Amneal Pharmaceuticals, Inc. $AMRX Shares Bought by Invesco Ltd.

Key Points

• Invesco Ltd. has increased its stake in Amneal Pharmaceuticals by 19.2%, now holding approximately 2.27 million shares worth about $19 million.
• Several other institutional investors, including Nantahala Capital Management and Vanguard Group, have also recently increased their stakes in Amneal Pharmaceuticals, indicating growing interest in the stock.
• Amneal Pharmaceuticals reported an earnings per share of $0.23 in its last quarter, surpassing analysts' expectations and maintaining a consensus rating of "Buy" with an average target price of $11.60.

Invesco Ltd. lifted its position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 19.2% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 2,272,713 shares of the company's stock after purchasing an additional 365,467 shares during the quarter. Invesco Ltd. owned about 0.73% of Amneal Pharmaceuticals worth $19,045,000 as of its most recent SEC filing.

Other institutional investors have also recently modified their holdings of the company. GAMMA Investing LLC raised its stake in shares of Amneal Pharmaceuticals by 5,975.0% in the first quarter. GAMMA Investing LLC now owns 3,159 shares of the company's stock worth $26,000 after purchasing an additional 3,107 shares during the last quarter. Headlands Technologies LLC purchased a new position in shares of Amneal Pharmaceuticals in the first quarter worth about $31,000. Amalgamated Bank raised its stake in shares of Amneal Pharmaceuticals by 33.0% in the first quarter. Amalgamated Bank now owns 5,511 shares of the company's stock worth $46,000 after purchasing an additional 1,367 shares during the last quarter. GF Fund Management CO. LTD. purchased a new position in Amneal Pharmaceuticals during the fourth quarter valued at approximately $52,000. Finally, Brevan Howard Capital Management LP purchased a new position in Amneal Pharmaceuticals during the fourth quarter valued at approximately $107,000. 31.82% of the stock is currently owned by hedge funds and other institutional investors.

Amneal Pharmaceuticals Trading Down 0.8%

AMRX traded down $0.08 during trading on Wednesday, hitting $9.31. The company's stock had a trading volume of 100,709 shares, compared to its average volume of 1,672,113. Amneal Pharmaceuticals, Inc. has a twelve month low of $6.68 and a twelve month high of $9.79. The business's fifty day simple moving average is $8.43 and its 200 day simple moving average is $8.03. The firm has a market capitalization of $2.92 billion, a price-to-earnings ratio of 931.43 and a beta of 1.11.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The company reported $0.23 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.17 by $0.06. Amneal Pharmaceuticals had a negative return on equity of 189.49% and a net margin of 0.12%. Amneal Pharmaceuticals has set its FY 2025 guidance at 0.700-0.750 EPS. As a group, equities research analysts forecast that Amneal Pharmaceuticals, Inc. will post 0.53 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on AMRX shares. The Goldman Sachs Group started coverage on Amneal Pharmaceuticals in a research report on Friday, June 6th. They set a "buy" rating and a $12.00 price target for the company. Wall Street Zen cut Amneal Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Tuesday, May 13th. Five investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus price target of $11.60.

Insider Transactions at Amneal Pharmaceuticals

In other news, EVP Jason B. Daly sold 22,000 shares of Amneal Pharmaceuticals stock in a transaction that occurred on Tuesday, August 12th. The stock was sold at an average price of $9.05, for a total value of $199,100.00. Following the sale, the executive vice president directly owned 10,606 shares of the company's stock, valued at $95,984.30. The trade was a 67.47% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Andrew S. Boyer sold 279,244 shares of Amneal Pharmaceuticals stock in a transaction that occurred on Wednesday, August 20th. The stock was sold at an average price of $9.38, for a total value of $2,619,308.72. Following the completion of the sale, the executive vice president directly owned 152,426 shares in the company, valued at $1,429,755.88. This represents a 64.69% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 577,206 shares of company stock valued at $5,405,265 over the last ninety days. Insiders own 17.45% of the company's stock.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.